<DOC>
	<DOCNO>NCT01365117</DOCNO>
	<brief_summary>Phase 1 clinical trial evaluate insulin exposure use different formulation Technosphere Insulin Inhalation Powder use Gen2 inhaler healthy normal volunteer .</brief_summary>
	<brief_title>Pharmacokinetic Study Healthy Volunteers</brief_title>
	<detailed_description>Phase 1 , single-center , open-label , randomize , crossover clinical trial evaluate insulin exposure use 3 U/mg 4 U/mg Technosphere Insulin Inhalation Powder formulation administer use Gen2 inhaler 31 healthy volunteer . Drop out replace . Each subject undergo screen visit either 4 5 day clinic stay dosing , depend randomization schedule .</detailed_description>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Nonsmoking ( within last 6 month ) men woman age 18 45 year consider healthy Body mass index ( BMI ) &lt; 32 kg/m2 FEV1 â‰¥ 80 % Third National Health Nutrition Examination Survey ( NHANES III ) predict Preexisting asthma chronic obstructive pulmonary disease ( COPD ) History coronary artery disease , peripheral vascular disease , congestive heart failure Blood donation within previous 3 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2012</verification_date>
</DOC>